REVA Medical, LLC today announced primary endpoint results from the MOTIV BTK randomized pivotal clinical trial evaluating the MOTIV(r) sirolimus-eluting bioresorbable vascular scaffold in patients with critical limb-threatening ischemia (CLTI).